You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK):IMM01(替達派西普)聯合IMM2510(珀維拉芙普α),另加化療或不加化療獲國家藥監局批准進行晚期惡性腫瘤治療的臨牀試驗
格隆匯 03-06 06:44

格隆匯3月6日丨宜明昂科-B(01541.HK)發佈公吿,集團已獲中國國家藥品監督管理局(“國家藥監局”)批准進行IMM01(替達派西普)聯合IMM2510(珀維拉芙普α),另加化療或不加化療用於治療晚期惡性腫瘤的臨牀試驗。這一重大進展標誌着公司在快速推進IMM01(替達派西普)及IMM2510(珀維拉芙普α)的臨牀研究方面又邁出了關鍵一步。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account